Vitamin D in schizophrenia: a clinical review.
Study Goal
The researchers aimed to explore the potential role of vitamin D in the development of schizophrenia and its metabolic comorbidities, rather than focusing on calcium directly.
Results Summary
The abstract suggests that vitamin D deficiency is linked to schizophrenia risk and metabolic issues, with potential benefits of supplementation for symptom improvement and physical health, but does not provide direct findings on calcium.
Population
Patients with severe mental illness, particularly schizophrenia.
Effective Dosage
Not mentioned
Duration
Not mentioned
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
vitamin D | neutral | calcium homeostasis and bone health | - | - | is known for its essential role | #1 |
vitamin D | neutral | brain development and normal brain function | - | - | is now considered as a potent neurosteroid hormone, critical | #2 |
vitamin D | neutral | various aspects of human health | - | - | is known for its anti-inflammatory property affecting | #3 |
vitamin D deficiency | neutral | - | patients with severe mental illness such as schizophrenia | - | is common in | #4 |
vitamin D deficiency | neutral | several environmental risk factors for schizophrenia | - | - | has been linked to | #5 |
vitamin D | neutral | schizophrenia | - | - | has a potential role in the development of | #6 |
neonatal vitamin D status | neutral | schizophrenia | - | - | is associated with the risk of developing | #7 |
vitamin D deficiency | neutral | obesity, insulin resistance, diabetes, hyperlipidaemia and cardiovascular disease | patients with schizophrenia | - | is related to | #8 |
vitamin D | neutral | schizophrenia | - | - | affects the manifestation of clinical symptoms and treatment response of | #9 |
vitamin D supplementation | increase | schizophrenia symptoms as well as physical health | patients with schizophrenia | - | has potential benefits to improve | #10 |
Vitamin D (vitD) is known for its essential role in calcium homeostasis and bone health. VitD is made endogenously in the skin from UVB radiation from sunlight. VitD is now considered as a potent neurosteroid hormone, critical to brain development and normal brain function, and is known for its anti-inflammatory property affecting various aspects of human health. VitD ligand-receptor, a receptor that mediates much of vitD's biological actions, has been found throughout the body including the central nervous system. VitD deficiency is common in patients with severe mental illness such as schizophrenia. Schizophrenia is a debilitating chronic mental illness characterised by positive symptoms, such as hallucinations and delusions, and negative symptoms including flat affect and lack of motivation. Several environmental risk factors for schizophrenia, such as season of birth, latitude and migration, have been linked to vitD deficiency. Recent studies have suggested a potential role of vitD in the development of schizophrenia. For example, neonatal vitD status is associated with the risk of developing schizophrenia in later life obesity, insulin resistance, diabetes, hyperlipidaemia and cardiovascular disease, which are commonly seen in patients with schizophrenia. It has been well established that vitD deficiency is related to these metabolic problems. The biological mechanism is most likely related to vitD's action on the regulation of inflammatory and immunological processes, consequently affecting the manifestation of clinical symptoms and treatment response of schizophrenia. Potential benefits of vitD supplementation to improve schizophrenia symptoms as well as physical health in patients with schizophrenia should be further explored in future studies.